Vir Biotechnology, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Shows company finances twice a year so investors can track progress and health.
Announces quarterly earnings and performance metrics investors need to evaluate the company.
Leadership changes affect company direction; investors monitor who manages money.
New board members help oversee company spending and protect shareholder interests.
Leadership transitions matter because board members watch over company decisions.
Shows company finances quarterly so investors track progress and health.
Announces quarterly earnings and performance metrics investors need to evaluate the company.
Stocky reads Vir Biotechnology, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Vir Biotechnology, Inc.'s most recent tracked filing was a 10-Q on 5 Aug 2026: Filed quarterly report for six months ended June 30, 2026.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.